Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
A Calcium channel blocker with spasmolytic activity on the intestine and antimuscarinic effects.
At latest update no published data were found on excretion into breast milk.
Pharmacokinetic data (moderately high molecular weight and high protein binding) make unlikely the passage into milk in significant amounts.
Its low oral bioavailability hinders its passage into infant's plasma from ingested milk, except in preterm infants and immediate neonatal period, since they may exhibit an increased intestinal permeability.
Anticholinergics may reduce milk production: take a minimum necessary dose and avoid prolonged treatment if decreased milk is observed.